A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Inthis study, MGCD0103, a new anticancer drug under investigation, is given three times
weekly in combination with gemcitabine to patients with solid tumours.